Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case–control study

Cancer Causes and Control

Volumn 26, Issue 7, 2015, Pages 973-981

  Brøns, Nanna ^a   Baandrup, Louise ^a   Dehlendorff, Christian ^a   Kjaer, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aspirin; Case control study; Chemoprevention; Endometrial cancer; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DENMARK; DRUG MEGADOSE; DRUG USE; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; NULLIPARA; OBESITY; PAIN; PARITY; PATIENT INFORMATION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SAMPLING; TREATMENT DURATION; VERY ELDERLY; CASE CONTROL STUDY; ENDOMETRIAL NEOPLASMS; ODDS RATIO; REGISTER; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; DENMARK; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; REGISTRIES; RISK FACTORS;

EID: 84930927477     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0578-4     Document Type: Article

References (44)

1. Sorosky JI (2012) Endometrial cancer. Obstet Gynecol 120:383–397
2. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P (2001) Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943:296–315
3. Siiteri PK (1978) Steroid hormones and endometrial cancer. Cancer Res 38:4360–4366
4. Modugno F, Ness RB, Chen C, Weiss NS (2005) Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev 14:2840–2847
5. Wallace AE, Gibson DA, Saunders PT, Jabbour HN (2010) Inflammatory events in endometrial adenocarcinoma. J Endocrinol 206:141–157
6. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM (2013) Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer 132:1146–1155
7. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130–140
8. Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259–267
9. Ohno S, Ohno Y, Suzuki N et al (2005) Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res 25:3679–3687
10. Kilic G, Gurates B, Garon J et al (2005) Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol 26:271–274
11. Gao J, Niwa K, Sun W et al (2004) Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 95:901–907
12. Ozalp SS, Eren CY, Bostancioglu RB, Koparal AT (2012) Induction of apoptosis and inhibition of cell proliferation by the cyclooxgenase enzyme blocker nimesulide in the Ishikawa endometrial cancer cell line. Eur J Obstet Gynecol Reprod Biol 164:79–84
13. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88:684–688
14. Sorensen HT, Friis S, Norgard B et al (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88:1687–1692
15. Danforth KN, Gierach GL, Brinton LA et al (2009) Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prev Res 2:466–472
16. Prizment AE, Folsom AR, Anderson KE (2010) Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 19:435–442
17. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146
18. Brasky TM, Moysich KB, Cohn DE, White E (2013) Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. Gynecol Oncol 128:113–119
19. Phipps AI, Anderson GL, Cochrane BB et al (2012) Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancer. Horm Cancer 3:240–248
20. Setiawan VW, Matsuno RK, Lurie G et al (2012) Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 21:1441–1449
21. Blenstrup LT, Knudsen LB (2011) Danish registers on aspects of reproduction. Scand J Public Health 39:79–82
22. Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39:42–45
23. Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39:91–94
24. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39:38–41
25. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33
26. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39:22–25
27. Rothman K, Greenland S, Lash TL, Rothman K, Greenland S, Lash TL (2008) Case-control studies. Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 111–127
28. Schmidt M, Hallas J, Friis S (2014) Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999–2012. Clin Epidemiol 6:155–168
29. ATC Classification Index with DDDs. World Health Organization Collaborating Centre for Drug Statistics Methodology.http://www.whocc.no/atc_ddd_index/. Accessed 16 Oct 2014
30. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920
31. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.http://www.R-project.org/. Accessed 2 Nov 2014
32. Brasky TM, Liu J, White E et al (2014) Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women’s Health Initiative. Int J Cancer 135:1869–1883
33. Fortuny J, Sima C, Bayuga S et al (2009) Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 18:1448–1456
34. Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS (2009) Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol 170:1512–1517
35. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE (2008) Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 68:2507–2513
36. Moysich KB, Baker JA, Rodabaugh KJ, Villella JA (2005) Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:2923–2928
37. Bosetti C, Bravi F, Talamini R, Montella M, Negri E, La VC (2010) Aspirin and risk of endometrial cancer: a case-control study from Italy. Eur J Cancer Prev 19:401–403
38. Cook NR, Lee IM, Zhang SM (2013) Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159:77–85
39. Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55
40. Cuzick J, Thorat MA, Bosetti C et al (2014) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. doi:10.1093/annonc/mdu225
41. Rothwell PM, Price JF, Fowkes FG (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602–1612
42. Purdie DM, Green AC (2001) Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 15:341–354
43. Harvey AE, Lashinger LM, Hursting SD (2011) The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 1229:45–52
44. Yood MU, Campbell UB, Rothman KJ et al (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961–968